HC Wainwright Reaffirms “Buy” Rating for Astria Therapeutics (NASDAQ:ATXS)

Astria Therapeutics (NASDAQ:ATXS)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They presently have a $16.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 149.03% from the stock’s previous close.

Several other research firms also recently issued reports on ATXS. Oppenheimer upped their target price on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th. JMP Securities assumed coverage on Astria Therapeutics in a research note on Friday, January 31st. They issued an “outperform” rating and a $26.00 price target on the stock. Finally, Citizens Jmp raised shares of Astria Therapeutics to a “strong-buy” rating in a research note on Friday, January 31st. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Astria Therapeutics has a consensus rating of “Buy” and an average target price of $25.67.

Astria Therapeutics Trading Up 1.2 %

Shares of ATXS stock traded up $0.08 during trading hours on Thursday, reaching $6.43. 33,778 shares of the company’s stock were exchanged, compared to its average volume of 258,454. The stock has a market cap of $362.56 million, a PE ratio of -3.07 and a beta of 0.68. The stock’s fifty day moving average price is $7.83 and its two-hundred day moving average price is $9.93. Astria Therapeutics has a 1 year low of $6.24 and a 1 year high of $16.90.

Institutional Trading of Astria Therapeutics

Several hedge funds have recently made changes to their positions in ATXS. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Astria Therapeutics by 13.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,452 shares of the biotechnology company’s stock valued at $567,000 after acquiring an additional 7,756 shares during the last quarter. Vestal Point Capital LP increased its stake in Astria Therapeutics by 4.5% in the fourth quarter. Vestal Point Capital LP now owns 4,180,000 shares of the biotechnology company’s stock valued at $37,369,000 after purchasing an additional 180,000 shares during the last quarter. Sphera Funds Management LTD. increased its stake in Astria Therapeutics by 2.4% in the fourth quarter. Sphera Funds Management LTD. now owns 139,800 shares of the biotechnology company’s stock valued at $1,250,000 after purchasing an additional 3,218 shares during the last quarter. Redmile Group LLC raised its holdings in Astria Therapeutics by 11.4% during the fourth quarter. Redmile Group LLC now owns 346,278 shares of the biotechnology company’s stock worth $3,096,000 after purchasing an additional 35,394 shares in the last quarter. Finally, ProShare Advisors LLC purchased a new stake in shares of Astria Therapeutics during the 4th quarter worth approximately $140,000. Institutional investors and hedge funds own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.